NEW YORK (GenomeWeb News) – Orion Genomics today said that it has licensed to Qiagen non-exclusive rights to its MethylScreen technology for epigenetics research.
Qiagen will use the MethylScreen technology in its EpiTect Methyl qPCR Array System reagent kits, which are used by researchers to analyze the DNA methylation status of genes with quantitative PCR.
Nathan Lakey, president and CEO of Orion Genomics, said in a statement that Qiagen's distribution capabilities will "further establish Orion's innovation among scientists studying epigenetics … [and] provides an additional source of revenue for Orion as we work to advance our own diagnostics products based on epigenetics and as we seek to expand our licensed distribution base among leading life science companies."
Financial and other terms of the deal were not disclosed.
In 2009 Orion entered into a non-exclusive licensing agreement and collaboration with Novartis covering the use of the MethylScreen technology for molecular diagnostic applications.